Impel Pharmaceuticals Inc (IMPL) Growth Rates Comparisons to Major Pharmaceutical Preparations Industry, Sector, Market. Sales, Income, EPS
CSIMarket Company Name, Ticker, Suppliers, else..
 
Impel Pharmaceuticals Inc   (NASDAQ: IMPL)
 

Impel Pharmaceuticals Inc Growth Comparisons

Select each growth Category to receive further Information




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

IMPL Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q3 MRQ) 55.52 % -4.57 % -0.57 % -0.67 %
Q / Q Revenue Growth (Q3 MRQ) -24.69 % -0.36 % 0.55 % -1.14 %
Y / Y Revenue Growth (for 12 months ending Q3 TTM) 149.81 % -5.42 % -2.85 % %
Sequential Revenue Growth (for 12 months ending Q3 TTM) 9.09 % -1.23 % -0.19 % 0.04 %
Revenue 5 Year Average Growth - 10.99 % 8.94 % 9.55 %


IMPL's Growth Comparisons in III. Quarter 2023




Impel Pharmaceuticals Inc showed impressive 55.52% year on year rise in the third quarter 2023 to 5 millions, despite the -4.57% in the Major Pharmaceutical Preparations industry, Healthcare sector decreased -0.57%. Although Major Pharmaceutical Preparations industry's Sales were softer then -0.67% overall market growth, Impel Pharmaceuticals Inc and the Healthcare sector have delivered above average market Sales.

Comparing company's Revenue to the second quarter results, sales were lower by -24.69% . On the annual basis, average annual sales growth for Impel Pharmaceuticals Inc is %, while S & P 500's including only Businesses with the third quarter 2023 results, average yearly sales growth is 9.55% over the past five years.


Growth Rates of IMPL's Income in the third quarter 2023


IMPL Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q3 MRQ) - -51.35 % -43.07 % 0.53 %
Sequential Operating Income Change (Q3 MRQ) - 34.98 % 33.59 % 7.86 %
Y / Y Operating Income Growth (Q3 TTM) - -26.93 % -25.69 % -9.48 %
Sequential Operating Income Growth (Q3 TTM) - -14.2 % -11.71 % -0.31 %
Operating Income 5 Year Avg. Change - 15.5 % 4.67 % 8.71 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q3 MRQ) - -72.53 % -80.3 % 1.33 %
Sequential Income from Cont. Ops. Change (Q3 MRQ) - 65.43 % 274.93 % 11.41 %
Y / Y Income from Cont. Ops. Change (Q3 TTM) - -58.66 % -54.07 % -9.41 %
Sequential Income from Cont. Ops. Change (Q3 TTM) - -30.54 % -29.11 % 0.17 %
Income from Cont. Ops. 5 Year Avg. Change - 16.52 % 8.32 % 11.88 %

IMPL Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q3 MRQ) - 22.25 % 3.05 % 6.99 %
Q / Q Net Income Growth (Q3 MRQ) - 683.38 % 2068.54 % 15.58 %
Y / Y Net Income Change (Q3 TTM) - -33.36 % -32.19 % -7.15 %
Sequential Net Income Change (Q3 TTM) - 10.16 % 2.42 % 1.71 %
Net Income 5 Year Avg. Growth - 21.26 % 10.49 % 3.58 %

IMPL's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q3 MRQ) - -72.69 % -80.3 % 1.33 %
Sequential EPS from Cont. Ops. Change (Q3 MRQ) - 246.36 % 274.93 % 11.41 %
Y / Y EPS from Cont. Ops. Change (Q3 TTM) - - - -
Sequential EPS from Cont. Ops. Change (Q3 TTM) - - - 117.26 %
EPS from Cont. Ops. 5 Year Avg. Growth - 4.91 % 8.32 % 11.88 %



IMPL EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q3 MRQ) - 21.55 % 3.05 % 11.88 %
Q / Q EPS Net Growth (Q3 MRQ) - 1540.14 % 2068.54 % 15.58 %
Y / Y EPS Net Change (for 12 months ending Q3 TTM) - - - 60266.88 %
Sequential EPS Net Change (for 12 months ending Q3 TTM) - - - 115.79 %
EPS Net 5 Year Avg. Change - 21.26 % 10.49 % 3.58 %



Impel Pharmaceuticals Inc reported bottom-line of $ -0.58 in the third quarter, compare to $ -1.31 in the same quarter a year ago. Major Pharmaceutical Preparations industry grew by 21.55%, while Healthcare sector increased by 3.05%, and overall market improved by 6.99%.

Comparing the company's EPS to the second quarter results, income per share were lower by -24.69% . On the annual basis, average annual income per share growth for Impel Pharmaceuticals Inc is %, while S & P 500's including only Businesses with the third quarter 2023 financial reports, average yearly income per share growth is 3.58% over the past five years.

IMPL Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q3 MRQ) - 6.55 % -3.77 % 25.44 %
Sequential Free Cash Flow Change (Q3 MRQ) - 152.51 % 64.54 % 29.02 %
Y / Y Free Cash Flow Change (Q3 TTM) - -19.71 % -18.36 % -3.19 %
Sequential Free Cash Flow Change (Q3 TTM) - 4.85 % 3.08 % 11.89 %
Free Cash Flow 5 Year Avg. Change - 8.35 % 6.34 % -24.89 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q3 MRQ) - 22.37 % 38.63 % -
Sequential Net Cash Flow Change (Q3 MRQ) - - - -
Y / Y Net Cash Flow Change (Q3 TTM) - - - -
Sequential Net Cash Flow Change (Q3 TTM) - - 11.14 % -
Net Cash Flow 5 Year Avg. Change - - -32.87 % 34.34 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q3 MRQ) 538 % 1.5 % 3.25 % 69.59 %
Sequential Capital Expenditures Change (Q3 MRQ) 625 % 6.34 % 5.53 % 16.4 %
Y / Y Capital Expenditures Change (Q3 TTM) 518.27 % 9.14 % 5.6 % -8.48 %
Sequential Capital Expenditures Change (Q3 TTM) 34.49 % 0.2 % 0.92 % 18.81 %
Capital Expenditures 5 Year Avg. Change - 13.14 % 9.46 % 8.57 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Y/Y Annual




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.